Letter seeks clarity on semaglutide compounding in California

Last week, we sent a letter to the California Board of Pharmacy requesting clarification of its position on compounding semaglutide.

The letter is the result of several reports of conflicting statements from California BOP staff that seemed to deviate from current FDA guidance on shortage drug compounding.

In a letter sent this week to NABP, FDA clarified its position on the compounding of semaglutide...

Earlier this week, FDA issued its first public statement on semaglutide compounding. The statement...

APC is always keeping track of what state boards of pharmacy are up to, and we’ll reach out when we...

Letter seeks clarity on semaglutide compounding in California

Related posts

FDA clarifies position on compounding semaglutide sodium

FDA issues public statement on compounded semaglutide

APC weighs in with several state BOPs